Farxiga® (Dapagliflozin) Tablets
Farxiga® (dapagliflozin) is a once-daily oral SGLT2 inhibitor used in adults with type 2 diabetes, heart failure, and chronic kidney disease. It helps lower blood sugar and provides cardiovascular and renal protection in appropriate patients.
What Is Farxiga®?
Farxiga® contains dapagliflozin, a sodium–glucose co-transporter 2 (SGLT2) inhibitor. It works in the kidneys to remove excess glucose from the bloodstream through urine.
It is marketed as Farxiga® in the United States and as Forxiga® in other regions. Regulatory oversight in the U.S. is provided by the U.S. Food and Drug Administration (FDA).
Indications
- Type 2 Diabetes Mellitus (T2DM): Improves glycaemic control alongside diet and exercise.
- Heart Failure (HF): Reduces the risk of hospitalization for heart failure.
- Chronic Kidney Disease (CKD): Slows progression of kidney disease and reduces associated risks in eligible patients.
Dosage and Administration
Route: Oral administration
- T2DM: 5 mg once daily; may increase to 10 mg once daily if additional control is needed.
- HF & CKD: 10 mg once daily.
- With or without food. Take at approximately the same time each day.
- Missed dose: Take when remembered unless close to next dose. Do not double doses.
Kidney function (eGFR) should be assessed before initiation and monitored periodically during treatment.
How Farxiga® Works
Dapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting urinary glucose excretion. In addition to lowering blood glucose, it may modestly reduce body weight and blood pressure. Cardiovascular and renal benefits extend beyond glucose control.
Common Side Effects
- Genital yeast infections
- Urinary tract infections
- Increased urination
- Thirst or mild dehydration
Serious but Rare Risks
- Diabetic ketoacidosis (DKA) — nausea, vomiting, abdominal pain, rapid breathing
- Severe dehydration or low blood pressure
- Hypoglycaemia when combined with insulin or sulfonylureas
Seek immediate medical attention if serious symptoms occur.
Who Should Not Use Farxiga®
- Patients receiving dialysis
- Individuals with hypersensitivity to dapagliflozin
- Pregnant or breastfeeding individuals (unless specifically advised by a healthcare provider)
Farxiga® vs. Jardiance®
Both Farxiga® (dapagliflozin) and Jardiance® (empagliflozin) are SGLT2 inhibitors taken once daily. They share similar mechanisms and benefits for blood sugar control, heart protection, and kidney support.
- Both reduce A1C and support cardiovascular outcomes.
- Side effect profiles are similar (genital infections, increased urination, rare DKA).
- Choice depends on kidney function, medical history, cost, and prescriber preference.
Everyday Tips
- Stay hydrated to reduce dizziness and dehydration risk.
- Sick-day planning: Ask your healthcare provider whether to pause therapy during acute illness or surgery.
- Monitor blood sugar and watch for symptoms of DKA.
- Store properly: Keep at room temperature in original packaging.
Buying Farxiga® Online
Farxiga® is a prescription-only medication. Patients purchasing online should ensure the pharmacy requires a valid prescription and complies with regulatory standards. Importation limits may apply for personal-use supplies.
